Cytosorbents Corporation filed its Q1 2026 results today — and the stock's 7% single-day drop tells most of the story before you even open the release.
Revenue of $8.86 million missed the consensus estimate of $9.36 million. Adjusted EPS of -$0.05 beat the -$0.06 estimate by a penny, but the top-line shortfall dominated the reaction. The miss lands in familiar territory: Germany, the company's largest direct market, declined 10% last year to $11.8 million, and management has been working through a regulatory detour on the DrugSorb-ATR device after deciding to slow down its FDA submission process. The bull case rests on improving gross margins — guided at 71%-74% for FY26 — and a target of operating cash-flow breakeven in the second half of the year. The bear case is that revenue growth, limited to 4% last year, looks structurally constrained while the regulatory timeline remains uncertain.
Short interest at 3.2% of free float is not the headline, and it hasn't been behaving dramatically. Shares short have barely moved over the past six weeks, oscillating in a narrow band around two million shares. Borrow is essentially free at 0.84% — up about 1.3% on the week, but still trivially cheap. Availability in the lending pool remains in normal territory: the ORTEX short score of 66.1 is modestly elevated but has been range-bound. Nothing in the short-side data is signalling a squeeze or a crowding event. Short sellers are present but not pressing.
Options positioning offers limited additional colour. The put/call ratio has held flat at 0.0132 for weeks — well below its 52-week high of 0.47. There is almost no active options hedging relative to what the market has supported in the past, which means either the options market sees little to hedge against, or it is simply illiquid at these price levels. Either way, the options surface is not generating a directional signal.
The only analyst tracked on CTSO comes from D. Boral Capital, where Jason Kolbert has maintained a Buy rating and a $10.00 target through multiple reaffirmations. That $10 target against a $0.59 stock — a gap of nearly 17x — is not a useful valuation anchor and should not be treated as one; the divergence suggests stale or structurally optimistic modelling. HC Wainwright held a Neutral with a $0.75 target as of late 2025, which is at least in the same order of magnitude as the current price. The top holder is Avenir Corporation with 8.3% of shares, followed by Vanguard at 3.5%. Skylands Capital trimmed its position by 147,000 shares in Q1 2026, and Phillip Chan and Vincent Capponi — both insiders — reduced holdings in early April. The most recent insider buy on record was the CEO's 100,000-share open-market purchase in November 2025 at $0.64, roughly in line with where the stock trades today.
After the prior earnings print on March 25, the stock fell 13.8% on the day and 21.3% over the following five sessions — the sharpest single-event drawdown in the recent history. The May 1 release saw a brief 1.7% gain on the day before fading slightly. Today's post-Q1 reaction has continued the pattern of heavy selling into results, even when the EPS line technically clears expectations.
The next meaningful focus is the H2 2026 cash-flow breakeven target and any updated FDA communication on DrugSorb-ATR — the two data points the market has been told to watch for signs that the operational recovery is on track.
See the live data behind this article on ORTEX.
Open CTSO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
